MedPath

A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)

Phase 3
Active, not recruiting
Conditions
Ulcerative Colitis (UC)
Interventions
Registration Number
NCT03006068
Lead Sponsor
AbbVie
Brief Summary

This study is designed to evaluate the long-term safety and efficacy of Upadacitinib in participants with ulcerative colitis (UC) who have not responded at the end of the induction period in Study M14-234 Substudy 1, who have had loss of response during the maintenance period of Study M14-234 Substudy 3, or who have successfully completed Study M14-234 Substudy 3.

Detailed Description

Not available

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
950
Inclusion Criteria

Note: Participants aged 16 or 17 may enroll in M14-234 or M14-675 where locally permissible

  • Participant has not achieved clinical response at the end of the induction period (Week 8) in Study M14-234 Substudy 1, has had loss of response during the maintenance period of Study M14-234 Substudy 3, or has successfully completed Study M14-234 Substudy 3. During the COVID-19 pandemic, for participants with missing endoscopy at Week 8, Week 16 or Week 52 due to the COVID-19 pandemic in Studies M14-234 Substudy 2, M14-234 Substudy 3 and M14-675, participants may be enrolled if certain criteria are met.
  • If female, participant must meet the contraception criteria.
  • Women of childbearing potential must have a negative urine pregnancy test at Week 0 visit.
  • Participant is judged to be in otherwise good health as determined by the principal investigator based upon clinical evaluations performed during the preceding study (Study M14-234).
  • Must be able and willing to give written informed consent and to comply with the requirements of this study protocol.
Exclusion Criteria
  • For any reason participant is considered by the investigator to be an unsuitable candidate.
  • Female participant with a positive pregnancy test at the final visit of Study M14-234 or who is considering becoming pregnant during the study or within 30 days after the last dose of study drug.
  • Known hypersensitivity to upadacitinib or its excipients or had any adverse event (AE) during the preceding studies, that in the investigator's judgment makes the participant unsuitable for this study.
  • Participant with an active or recurrent infection that based on the investigator's clinical assessment makes the participant an unsuitable candidate for the study. Participants with ongoing infections undergoing treatment may be enrolled BUT NOT dosed until the infection has been successfully treated.
  • Current evidence of active tuberculosis (TB); current evidence of latent tuberculosis and for any reason the participant cannot take full course of TB prophylaxis treatment as required per protocol.
  • Participant with a poorly controlled medical condition, such as uncontrolled diabetes, unstable ischemic heart disease, moderate or severe congestive heart failure (New York Heart Association class III or IV), recent cerebrovascular accidents and any other condition which, in the opinion of the investigator or sponsor, would put the subject at risk by participation in this study.
  • Participants have malignancy, high-grade dysplasia, un-removed low-grade dysplasia of the gastrointestinal tract diagnosed at the endoscopy performed at the final visit of Study M14-234.
  • History of any malignancy except for successfully treated nonmelanoma skin cancer (NMSC) or localized carcinoma in situ of the cervix from evaluations performed in Study M14-234.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Participants receiving Upadacitinib (ABT-494) Dose AUpadacitinib (ABT-494)The participants in this arm will receive Upadacitinib (ABT-494) dose A.
Participants receiving Upadacitinib (ABT-494) Dose BUpadacitinib (ABT-494)The participants in this arm will receive Upadacitinib (ABT-494) dose B.
Participants receiving Upadacitinib (ABT-494) Dose CUpadacitinib (ABT-494)The participants in this arm will receive Upadacitinib (ABT-494) dose C.
Participants receiving PlaceboPlaceboThe participants in this arm will receive placebo until study is unblinded.
Participants receiving Upadacitinib (ABT-494) Dose A or Dose BUpadacitinib (ABT-494)The participants in this arm will receive Upadacitinib (ABT-494) dose A or dose B.
Primary Outcome Measures
NameTimeMethod
Assessing Treatment-Emergent Adverse EventsUp to 288 Weeks

Treatment-emergent adverse events are defined as events that begin or worsen either on or after the first dose of the study drug and within 30 days after the last dose of the study drug in the analysis period.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (492)

East View Medical Research, LLC /ID# 171184

🇺🇸

Mobile, Alabama, United States

CB Flock Research Corporation /ID# 165986

🇺🇸

Mobile, Alabama, United States

Delsol Research Management, Ll /Id# 170130

🇺🇸

Chandler, Arizona, United States

Digestive Disease Consultants, A Division of Arizona Digestive Health, P.C /ID# 211886

🇺🇸

Mesa, Arizona, United States

Arizona Arthritis & Rheumatology Research, PLLC /ID# 169823

🇺🇸

Sun City, Arizona, United States

Adobe Clinical Research LLC /ID# 155249

🇺🇸

Tucson, Arizona, United States

University of Arizona /ID# 150568

🇺🇸

Tucson, Arizona, United States

Citrus Valley Gastroenterology /ID# 151915

🇺🇸

Covina, California, United States

Newport Huntington Medical Group /ID# 217006

🇺🇸

Huntington Beach, California, United States

UC San Diego Health System /ID# 155187

🇺🇸

La Jolla, California, United States

Scroll for more (482 remaining)
East View Medical Research, LLC /ID# 171184
🇺🇸Mobile, Alabama, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.